Teva Pharmaceutical Industries Ltd. March 26 announced that the Food and Drug Administration has approved Qnasl (beclomethasone dipropionate), a new “dry” nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years old and older.
Qnasl is delivered as a once-daily, pressurized, hydrofluoroalkane (HFA)-propelled nonaqueous aerosol that is environmentally friendly, the Jerusalem-based company said. Previously, only aqueous formulations of corticosteroids were available.
The product is expected to be available by prescription in April, Teva said.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.